233 related articles for article (PubMed ID: 29784748)
1. Emerging Treatment Options for Acute Lymphoblastic Leukemia: Focus on CAR T-Cell Therapy.
Brown PA; Shah B
J Natl Compr Canc Netw; 2018 May; 16(5S):651-655. PubMed ID: 29784748
[TBL] [Abstract][Full Text] [Related]
2. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
3. How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?
Gökbuget N
Best Pract Res Clin Haematol; 2017 Sep; 30(3):261-274. PubMed ID: 29050699
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed/refractory acute lymphoblastic leukemia.
Paul S; Rausch CR; Nasnas PE; Kantarjian H; Jabbour EJ
Clin Adv Hematol Oncol; 2019 Mar; 17(3):166-175. PubMed ID: 30969955
[TBL] [Abstract][Full Text] [Related]
5. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
6. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
7. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
Yilmaz M; Kantarjian H; Ravandi-Kashani F; Short NJ; Jabbour E
Clin Adv Hematol Oncol; 2018 Mar; 16(3):216-223. PubMed ID: 29742077
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the treatment of acute lymphoblastic leukemia.
Rafei H; Kantarjian HM; Jabbour EJ
Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
[TBL] [Abstract][Full Text] [Related]
9. Adult Acute Lymphoblastic Leukemia.
Paul S; Kantarjian H; Jabbour EJ
Mayo Clin Proc; 2016 Nov; 91(11):1645-1666. PubMed ID: 27814839
[TBL] [Abstract][Full Text] [Related]
10. Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia.
Ma Q; Zhang J; O'Brien E; Martin AL; Agostinho AC
J Comp Eff Res; 2020 Aug; 9(12):849-860. PubMed ID: 32602756
[No Abstract] [Full Text] [Related]
11. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
[TBL] [Abstract][Full Text] [Related]
12. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
Advani A
Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
Sikaria S; Aldoss I; Akhtari M
Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia.
Moskop A; Pommert L; Thakrar P; Talano J; Phelan R
Pediatr Blood Cancer; 2021 Jan; 68(1):e28739. PubMed ID: 33009894
[TBL] [Abstract][Full Text] [Related]
16. Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments.
Xu X; Huang S; Xiao X; Sun Q; Liang X; Chen S; Zhao Z; Huo Z; Tu S; Li Y
Front Immunol; 2020; 11():569117. PubMed ID: 33643279
[TBL] [Abstract][Full Text] [Related]
17. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.
Lanza F; Maffini E; Saraceni F; Massari E; Rondoni M; Daghia G; Olivieri A; Cerchione C; Martinelli G
Minerva Med; 2020 Oct; 111(5):478-490. PubMed ID: 32955830
[TBL] [Abstract][Full Text] [Related]
18. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
Jacoby E; Bielorai B; Avigdor A; Itzhaki O; Hutt D; Nussboim V; Meir A; Kubi A; Levy M; Zikich D; Zeltzer LA; Brezinger K; Schachter J; Nagler A; Besser MJ; Toren A
Am J Hematol; 2018 Dec; 93(12):1485-1492. PubMed ID: 30187944
[TBL] [Abstract][Full Text] [Related]
19. Novel Therapies in Acute Lymphoblastic Leukemia.
Phelan KW; Advani AS
Curr Hematol Malig Rep; 2018 Aug; 13(4):289-299. PubMed ID: 30078158
[TBL] [Abstract][Full Text] [Related]
20. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
Kantarjian H; Jabbour E
Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
